A detailed history of State Street Corp transactions in Savara Inc stock. As of the latest transaction made, State Street Corp holds 3,578,034 shares of SVRA stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,578,034
Previous 1,880,064 90.31%
Holding current value
$13.7 Million
Previous $9.36 Million 54.02%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $6.21 Million - $9.07 Million
1,697,970 Added 90.31%
3,578,034 $14.4 Million
Q1 2024

May 15, 2024

BUY
$4.19 - $5.59 $469,326 - $626,141
112,011 Added 6.34%
1,880,064 $9.36 Million
Q4 2023

Feb 14, 2024

BUY
$3.18 - $4.9 $733,750 - $1.13 Million
230,739 Added 15.01%
1,768,053 $8.31 Million
Q3 2023

Nov 14, 2023

BUY
$2.97 - $3.88 $578,413 - $755,637
194,752 Added 14.51%
1,537,314 $5.81 Million
Q2 2023

Aug 14, 2023

BUY
$1.69 - $3.24 $1.82 Million - $3.48 Million
1,074,551 Added 400.94%
1,342,562 $4.28 Million
Q4 2022

Feb 14, 2023

SELL
$1.11 - $1.64 $3,996 - $5,904
-3,600 Reduced 1.33%
268,011 $415,000
Q1 2022

May 16, 2022

BUY
$1.05 - $1.36 $31,565 - $40,884
30,062 Added 12.45%
271,611 $356,000
Q3 2021

Nov 15, 2021

BUY
$1.18 - $1.64 $8,142 - $11,316
6,900 Added 2.94%
241,549 $333,000
Q2 2021

Aug 16, 2021

SELL
$1.51 - $2.29 $861,891 - $1.31 Million
-570,789 Reduced 70.87%
234,649 $399,000
Q1 2021

May 17, 2021

BUY
$1.17 - $2.33 $112,922 - $224,879
96,515 Added 13.61%
805,438 $1.68 Million
Q4 2020

Feb 16, 2021

SELL
$1.0 - $1.47 $16,399 - $24,106
-16,399 Reduced 2.26%
708,923 $815,000
Q3 2020

Nov 10, 2020

SELL
$1.09 - $2.21 $14,431 - $29,260
-13,240 Reduced 1.79%
725,322 $791,000
Q2 2020

Aug 14, 2020

BUY
$1.8 - $3.05 $331,219 - $561,233
184,011 Added 33.18%
738,562 $1.84 Million
Q1 2020

May 11, 2020

BUY
$1.91 - $4.08 $1.06 Million - $2.26 Million
554,551 New
554,551 $1.18 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $436M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.